摘要
YAP1和转录共激活因子与PDZ结合基序与许多转录因子一起调控基因转录。YAP1和TAZ由肿瘤抑制性的Hippo病理通路负面地调控,在人类肿瘤中,Hippo通路经常失去控制并且YAP1和TAZ能躲避Hippo通路的抑制,YAP1和TAZ的上调诱导了上皮细胞间质转化与肿瘤细胞耐药性增加。TAZ与肿瘤干细胞有关,结果是与高度表达的YAP1和TAZ肿瘤与临床预后有关。YAP1和TAZ的抑制剂被认为在肿瘤治疗中是有益的。另一方面,因为YAP1和TAZ在各种组织干细胞和组织修复的调节中起着非常重要的角色,YAP1和TAZ的激活物在再生医学中很有用。本文讨论了YAP1和TAZ的抑制剂和激活剂在人类疾病中潜在的应用和综述了检索这些制剂的药物筛选的过程。
关键词: 肿瘤,药物筛选,再生,肌肉减少症,肿瘤抑制剂
图形摘要
Current Drug Targets
Title:The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine
Volume: 18 Issue: 4
关键词: 肿瘤,药物筛选,再生,肌肉减少症,肿瘤抑制剂
摘要: Yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding motif (TAZ) co-operate with numerous transcription factors to regulate gene transcriptions. YAP1 and TAZ are negatively regulated by the tumor suppressive Hippo pathway. In human cancers, the Hippo pathway is frequently deregulated and YAP1 and TAZ escape the inhibition by the Hippo pathway. The upregulation of YAP1 and TAZ induces epithelial-mesenchymal transition and increases drug resistance in cancer cells. TAZ is implicated in cancer stemness. In consequence cancers with hyperactive YAP1 and TAZ are associated with poor clinical prognosis. Inhibitors of YAP1 and TAZ are reasoned to be beneficial in cancer therapy. On the other hand, since YAP1 and TAZ play important roles in the regulation of various tissue stem cells and in tissue repair, activators of YAP1 and TAZ are useful in the regenerative medicine. We discuss the potential application of inhibitors and activators of YAP1 and TAZ in human diseases and review the progress of drug screenings to search for them.
Export Options
About this article
Cite this article as:
The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine, Current Drug Targets 2017; 18 (4) . https://dx.doi.org/10.2174/1389450117666160112115641
DOI https://dx.doi.org/10.2174/1389450117666160112115641 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy
Current Pharmaceutical Design Understanding and Managing Oral Bioavailability: Physiological Concepts and Patents
Recent Patents on Anti-Cancer Drug Discovery Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs
Current Pharmaceutical Design Anticancer Properties of Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening The Role of Adenosine in Bone: An Emerging Concept
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Antiangiogenic Triterpenes Isolated from Chinese Herbal Medicine Actinidia chinensis Planch
Anti-Cancer Agents in Medicinal Chemistry Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Sirtuin Family: A Link to Metabolic Signaling and Senescence
Current Medicinal Chemistry Angiogenesis in Glioblastoma Multiforme: Navigating the Maze
Anti-Cancer Agents in Medicinal Chemistry Small Molecules as SIRT Modulators
Mini-Reviews in Medicinal Chemistry ICH Q8 Guidelines in Practice: Spray Drying Process Optimization by 2<sup>3</sup> Factorial Design for the Production of Famotidine Nanoparticles
Pharmaceutical Nanotechnology Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Editorial: “Strategies and Methods to Prevent Fluoropyrimidine-associated Toxicities”
Clinical Cancer Drugs Editorial (Thematic Issue: Optimizing Treatment in Rheumatoid Arthritis)
Current Pharmaceutical Design Current Status and Future Directions of Multimodality Therapy for Non- Small Cell Lung Cancer of the Superior Sulcus
Current Cancer Therapy Reviews Microbubbles: A Novel Strategy for Chemotherapy
Current Pharmaceutical Design What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine